Not Easier, But Better Drugs

Ideas to shift drug development to processes based on network biology and polypharmacology are an increasingly relevant topic in the scientific literature. Dr. Scott Lusher, an expert on leveraging “big data,” warns that coupled to the new methodologies proposed is the need to change the way that data are summarized, visualized and interpreted to inform drug design.

Read about his thoughts on data-driven decisions in the drug design cycle. (PDF, 698kb)